HR+/HER2- ADVANCED BREAST CANCER
Clinical trials for HR+/HER2- ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis early-phase trial tested two oral drugs, dalpiciclib and chidamide, in 22 people with HR+/HER2- advanced breast cancer whose disease had worsened after CDK4/6 inhibitor therapy. The main goal was to find the safest dose. Researchers also looked at how well the combination sh…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ribociclib shows promise in indian women with advanced breast cancer
Disease control CompletedThis study looked at how well the drug ribociclib works in real-world settings for Indian women with a common type of advanced breast cancer (HR+, HER2-). Researchers reviewed medical records of 335 patients treated across 18 sites in India. The goal was to measure how long the d…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Real-world data may reveal true effectiveness of leading breast cancer therapy
Knowledge-focused CompletedThis study looks at medical records from across Europe to see how well a drug combination (palbociclib plus an aromatase inhibitor) works as a first treatment for people with a common type of advanced breast cancer (HR+/HER2-). Researchers want to understand how long the treatmen…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Real-world data on palbociclib combo for breast cancer in japan
Knowledge-focused CompletedThis study looked back at medical records of 693 Japanese patients with a certain type of advanced breast cancer (HR+/HER2-) who received palbociclib plus endocrine therapy as their first or second treatment. Researchers measured how long patients lived without the cancer getting…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Polish breast cancer treatment patterns revealed in new study
Knowledge-focused CompletedThis study observed 440 adults in Poland with advanced HR+ HER2- breast cancer to understand how doctors treat the disease in everyday practice. Researchers tracked treatment choices, changes over one year, and how they relate to patient characteristics and guidelines. The goal w…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Russian breast cancer study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study observed over 2,400 women in Russia with advanced HR+/HER2- breast cancer to see how well different treatments work in everyday medical practice. Researchers tracked how long patients stayed on their therapy before it stopped working or caused side effects. The goal wa…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Japanese breast cancer survival data reviewed for palbociclib combo
Knowledge-focused CompletedThis completed study in Japan reviewed medical records of 42 patients with HR+/HER2- advanced breast cancer who had been treated with palbociclib plus letrozole. The goal was to see how long patients lived after starting this treatment. It was a follow-up to an earlier phase 2 st…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC